AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma, Inc. Class A (AEON)
Company Research
Source: GlobeNewswire
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company’s Compensation Committee of the Board of Directors (the “Compensation Committee”) approved the grant of inducement awards. The Compensation Committee approved the grant to Mr. Bencich of 754,717 restricted stock units (“RSUs”) under AEON’s 2025 Employment Inducement Incentive Award Plan (the “Inducement Plan”), which provides for the granting of equity awards to new employees of the Company. The RSUs vest over four years, 25% on each annual anniversary of March 9, 2026, which was Mr. Bencich’s employment start date. In addition, the Compensation Committee approved the grant to Mr. B
Show less
Read more
Impact Snapshot
Event Time:
AEON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AEON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AEON alerts
High impacting AEON Biopharma, Inc. Class A news events
Weekly update
A roundup of the hottest topics
AEON
News
- AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing StandardsGlobeNewswire
- AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar ProgramGlobeNewswire
- AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar ProgramGlobeNewswire
- AEON Biopharma Appoints John Bencich as Chief Financial OfficerGlobeNewswire
- AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual MeetingGlobeNewswire
AEON
Sec Filings
- 4/3/26 - Form 3
- 4/3/26 - Form 4
- 3/11/26 - Form 4
- AEON's page on the SEC website